ANGIOFLUX Sulodexide 250LSU Soft Gel Capsule 1's
We recognize that purchasing medications can be a deeply personal matter. To respect your privacy, we ensure that all orders are packaged discreetly, with no indication of the contents on the packaging. This means that even our couriers remain unaware of the package contents.
Furthermore, we uphold strict confidentiality standards. We guarantee that your order information will never be disclosed to any third party. Your trust is paramount to us, and we are committed to safeguarding your privacy at every step of the process. Our dedication to discretion and confidentiality is part of our unwavering commitment to you, our valued customer.
Features
- Sulodexide
Description
Indications/Uses
Dosage/Direction for Use
Administration
Contraindications
As the molecular structure is similar to heparin, do not administer sulodexide (Angioflux) to patients hypersensitive to heparin and heparinoids.
Warnings
Special Precautions
Use In Pregnancy & Lactation
For cautionary reasons, we advise against use during pregnancy, even if the fetal toxicity studies have not demonstrated any embryo-fetus toxicity.
Adverse Reactions
Drug Interactions
Storage
Action
The main mechanism can be identified in a dose-dependent inhibition of the activated coagulation factor X, while the limited interference effect with thrombin avoid the consequences of an anticoagulant action. Sulodexide (Angioflux) exerts potent lipolytic activity, as well as activity related to proteoglycan synthesis by smooth muscle cells, associated with suppression of cell proliferation and inhibition of a significant part of atheromatous plaque development. At the same time, sulodexide (Angioflux) inhibits migration of smooth muscle cells towards the innermost layer, as a result of the drug's antithrombin and anti-platelet aggregation effect. The marked efficacy of sulodexide (Angioflux) derives from its dual action of catalyzing the inhibition of thrombin by antithrombin III (ATIII) and by heparin cofactor II (HCII), with the added advantage of not increasing bleeding. Sulodexide (Angioflux) possesses marked systemic fibrinolytic activity due to the liberation of tissue plasminogen activator (tPA), with marked functional and antigenic reduction of plasminogen activator inhibitor-1 (PAI-1), and a reduction in plasma fibrinogen concentration, favoring the reduction of blood viscosity.
In summary, sulodexide (Angioflux) has very effective antithrombotic and antithrombin activity, with efficacy and safety demonstrated in a wide range of vascular pathologies.